Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin
{"title":"强脉冲光与 0.05% 环孢素 a 外用眼药水联合治疗与斯约格伦综合征有关的干眼症的效果。","authors":"Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin","doi":"10.1080/1744666X.2024.2358157","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to assess the effectiveness and safety of intense pulsed light (IPL) therapy plus topical 0.05% cyclosporine A (CsA) eye drops to treat Sjögren's Syndrome-related dry eyes (SS-DE).</p><p><strong>Research design and methods: </strong>In this prospective, randomized trial included, 60 individuals with SS-DE symptoms were randomized to receive topical eye drops containing either 0.1% sodium hyaluronate (Group S) or 0.05% CsA (Group C) plus IPL therapy. Before the first treatment (baseline), and at 12, 16, and 20 weeks after treatment commencement, we assessed the best corrected visual acuity (BCVA), the Ocular Surface Disease Index (OSDI) score, the Schirmer I test (SIT), noninvasive tear breakup time (NBUT), corneal fluorescein staining (CFS), meibomian gland (MG) dropout, lid margin abnormality, MG expressibility, and meibum quality.</p><p><strong>Results: </strong>Both groups showed significant improvements in the OSDI, NBUT, CFS, MG expressibility, and meibum quality (all <i>p</i> < 0.05). Group C showed a greater increase in OSDI, NBUT, MG expressibility, and meibum quality (all <i>p</i> < 0.05). Moreover, SIT and lid margin abnormalities significantly improved in Group C (both <i>p</i> < 0.05), but not in Group S.</p><p><strong>Conclusion: </strong>Treatment with 0.05% CsA eyedrops plus IPL therapy could significantly reduce the issues and physical discomfort of patients with SS-DE.</p><p><strong>Clinical trial: </strong>Registered on 20 July 2021, with the registration number ChiCTR2100049059.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1261-1267"},"PeriodicalIF":3.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye.\",\"authors\":\"Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin\",\"doi\":\"10.1080/1744666X.2024.2358157\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study aimed to assess the effectiveness and safety of intense pulsed light (IPL) therapy plus topical 0.05% cyclosporine A (CsA) eye drops to treat Sjögren's Syndrome-related dry eyes (SS-DE).</p><p><strong>Research design and methods: </strong>In this prospective, randomized trial included, 60 individuals with SS-DE symptoms were randomized to receive topical eye drops containing either 0.1% sodium hyaluronate (Group S) or 0.05% CsA (Group C) plus IPL therapy. Before the first treatment (baseline), and at 12, 16, and 20 weeks after treatment commencement, we assessed the best corrected visual acuity (BCVA), the Ocular Surface Disease Index (OSDI) score, the Schirmer I test (SIT), noninvasive tear breakup time (NBUT), corneal fluorescein staining (CFS), meibomian gland (MG) dropout, lid margin abnormality, MG expressibility, and meibum quality.</p><p><strong>Results: </strong>Both groups showed significant improvements in the OSDI, NBUT, CFS, MG expressibility, and meibum quality (all <i>p</i> < 0.05). Group C showed a greater increase in OSDI, NBUT, MG expressibility, and meibum quality (all <i>p</i> < 0.05). Moreover, SIT and lid margin abnormalities significantly improved in Group C (both <i>p</i> < 0.05), but not in Group S.</p><p><strong>Conclusion: </strong>Treatment with 0.05% CsA eyedrops plus IPL therapy could significantly reduce the issues and physical discomfort of patients with SS-DE.</p><p><strong>Clinical trial: </strong>Registered on 20 July 2021, with the registration number ChiCTR2100049059.</p>\",\"PeriodicalId\":12175,\"journal\":{\"name\":\"Expert Review of Clinical Immunology\",\"volume\":\" \",\"pages\":\"1261-1267\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Clinical Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1744666X.2024.2358157\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2024.2358157","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
研究目的本研究旨在评估强脉冲光（IPL）疗法加外用 0.05% 环孢素 A（CsA）滴眼液治疗斯约格伦综合征相关干眼症（SS-DE）的有效性和安全性：在这项前瞻性随机试验中，60名有SS-DE症状的患者被随机分配接受含0.1%透明质酸钠的局部滴眼液（S组）或含0.05% CsA的局部滴眼液（C组）以及IPL疗法。在首次治疗前（基线）、治疗开始后的 12 周、16 周和 20 周，我们评估了最佳矫正视力（BCVA）、眼表疾病指数（OSDI）评分、Schirmer I 测试（SIT）、无创泪液破裂时间（NBUT）、角膜荧光素染色（CFS）、睑板腺脱落（MG）、睑缘异常、睑板腺表达能力和睑板腺质量：结果：两组患者的 OSDI、NBUT、CFS、MG 表现力和睑板腺质量均有明显改善（均为 p p p 结论）：使用 0.05% CsA 眼药水加 IPL 治疗可明显减轻 SS-DE 患者的问题和身体不适：临床试验：2021年7月20日注册，注册号为ChiCTR2100049059。
The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye.
Objectives: This study aimed to assess the effectiveness and safety of intense pulsed light (IPL) therapy plus topical 0.05% cyclosporine A (CsA) eye drops to treat Sjögren's Syndrome-related dry eyes (SS-DE).
Research design and methods: In this prospective, randomized trial included, 60 individuals with SS-DE symptoms were randomized to receive topical eye drops containing either 0.1% sodium hyaluronate (Group S) or 0.05% CsA (Group C) plus IPL therapy. Before the first treatment (baseline), and at 12, 16, and 20 weeks after treatment commencement, we assessed the best corrected visual acuity (BCVA), the Ocular Surface Disease Index (OSDI) score, the Schirmer I test (SIT), noninvasive tear breakup time (NBUT), corneal fluorescein staining (CFS), meibomian gland (MG) dropout, lid margin abnormality, MG expressibility, and meibum quality.
Results: Both groups showed significant improvements in the OSDI, NBUT, CFS, MG expressibility, and meibum quality (all p < 0.05). Group C showed a greater increase in OSDI, NBUT, MG expressibility, and meibum quality (all p < 0.05). Moreover, SIT and lid margin abnormalities significantly improved in Group C (both p < 0.05), but not in Group S.
Conclusion: Treatment with 0.05% CsA eyedrops plus IPL therapy could significantly reduce the issues and physical discomfort of patients with SS-DE.
Clinical trial: Registered on 20 July 2021, with the registration number ChiCTR2100049059.
期刊介绍：
Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology.
Articles focus on the following key areas:
• Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines
• Performance and benefits of newly approved therapeutic agents
• New diagnostic approaches
• Screening and patient stratification
• Pharmacoeconomic studies
• New therapeutic indications for existing therapies
• Adverse effects, occurrence and reduction
• Prospects for medicines in late-stage trials approaching regulatory approval
• Novel treatment strategies
• Epidemiological studies
• Commentary and comparison of treatment guidelines
Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
